MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year.

EZH2 inhibitors enhance effectiveness of cancer immunotherapies

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by

December 6, 2024

Simone Song’s ORI Capital closes $260M second fund after CG Oncology success

Simone Song recalls discussing oncolytic virus therapies with her father and son “under the moonlight, like a family scientific symposium” in Southern California in 2014.

February 23, 2024

Immune protein Ku70 key in fighting bowel cancer

Study establishes Ku70’s role in tumor suppression, showing that reduced expression or mutations in this DNA repair protein significantly increase intestinal cancer risk.

January 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.